The alarming and rising costs of diabetes and prediabetes: A call for action!

Diabetes Care

Volumn 37, Issue 12, 2014, Pages 3137-3138

  Cefalu, William T ^a   Petersen, Matthew P ^b   Ratner, Robert E ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b AMERICAN DIABETES ASSOCIATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASYMPTOMATIC DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; DIABETES MELLITUS; EDITORIAL; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; PATIENT CARE; PREVALENCE; PREVENTIVE HEALTH SERVICE; SCREENING; FEMALE; MALE; PREGNANCY;

FEMALE; HUMANS; MALE; PREGNANCY;

EID: 84911898592     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2329     Document Type: Editorial

References (15)

1. Geiss LS, Wang J, Cheng YJ, et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. JAMA 2014;312:1218-1226
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046
3. Dall TM, Yang W, Halder P, et al. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetesmellitus, and prediabetes. Diabetes Care 2014;37:3172-3179
4. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014;370:1514-1523
5. Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff (Millwood) 2010;29:297-303
6. Yudkin JS, Montori VM. The epidemic of prediabetes: the medicine and the politics. BMJ 2014;349:g4485
7. Herman WH, Hoerger TJ, Brandle M, et al.; Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323-332
8. Ratner R, Goldberg R, Haffner S, et al.; Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005;28:888-894
9. Gregg EW, Cadwell BL, Cheng YJ, et al. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 2004;27:2806-2812
10. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA, U.S. Department of Health and Human Services, 2014
11. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDMoccurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-819
12. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34:877-890
13. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
14. Bang H, Edwards AM, Bomback AS, et al. Development and validation of a patient selfassessment score for diabetes risk. Ann Intern Med 2009;151:775-783
15. U.S. Preventive Services Task Force. Draft Evidence Review: abnormal glucose and type 2 diabetes mellitus in adults: screening [Internet], 2014. Available from http://www.uspreventiveservicestaskforce.org/Page/Document/EvidenceReportDraft/screening-for-abnormal-glucose-and-type-2-diabetes-mellitus. Accessed 14 October 2014